Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Thyroid carcinoma is rare among human malignancies (! 1%) but is the most frequent
endocrine cancer, accounting for about 5% of thyroid nodules (1). The latter are very …

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …

Background It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective
as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid …

Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of
differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear …

Abstract Context: Thyroglobulin autoantibodies (TgAb) are primarily measured in serum in
conjunction with thyroglobulin (Tg)—the primary tumor marker used to monitor patients with …

Pediatric thyroid cancer is a rare disease with an excellent prognosis. Compared with adults,
epithelial-derived differentiated thyroid cancer (DTC), which includes papillary and follicular …

Thyroglobulin autoantibodies (TgAb) are detected at diagnosis or during treatment in
approximately 25% of patients with differentiated thyroid cancer (DTC). When present, TgAb …

Objective To summarize the definitions of and management recommendations for low-risk
thyroid cancer made by the American and European Thyroid Associations and synthesize …

Background: Radioactive iodine (RAI) remnant ablation has been used to eliminate normal
thyroid tissue and may also facilitate monitoring for persistent or recurrent thyroid carcinoma …